On July 23, Medpace rose 15.54% overnight, trading at $610.21/share. The surge was driven by the company reporting Q2 results that significantly exceeded market expectations, coupled with an upward revision to full-year guidance.

Medpace posted Q2 EPS of $4.25, beating the analyst consensus estimate of $3.97-$3.98 by approximately 7%, representing a 37.1% year-over-year increase from $3.10. Revenue reached $707.3 million, surpassing estimates of $687.6-$689.5 million, up from $603.3 million a year earlier. Net income for the quarter was $121.4 million. New business awards totaled $795.7 million, up 28.2% year-over-year, resulting in a net book-to-bill ratio of 1.13x.

For full-year guidance, the company expects revenue of $2.81 billion to $2.89 billion, above the FactSet estimate of $2.77 billion, and EPS of $17.25 to $17.95, exceeding the consensus estimate of $16.97. The dual catalysts of a comprehensive earnings beat and raised guidance fueled significant buying interest.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)